Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
There has been little discussion in the medical literature regarding the process whereby physicians elect to accept or reject the incorporation of results of randomized trials into their routine clinical practice. This decision-making process has the potential to result in serious ethical dilemmas.
Markman
Maurie
M
University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA. mmarkman@mdanderson.org
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003657:Decision Making / Q000941:ethics; D026690:Ethics, Clinical; D019317:Evidence-Based Medicine / Q000941:ethics / Q000592:standards*; D006801:Humans; D008495:Medical Oncology / Q000193:education / Q000941:ethics* / Q000379:methods* / Q000592:standards; D009369:Neoplasms / Q000628:therapy; D010820:Physicians / Q000941:ethics* / Q000523:psychology / Q000592:standards; D016032:Randomized Controlled Trials as Topic / Q000592:standards
D000970:Antineoplastic Agents